The goal of this interventional study is to create hepatocellular carcinoma organoids from liver bioptic samples of individuals with hepatocellular carcinoma. The main questions it aims to answer are: * the feasibility of hepatocellular carcinoma organoids integrated with host gut microbiota and peripheral blood mononuclear cells * the molecular pattern of the organoid tumor microenvironment * the in vitro therapeutic response of hepatocellular carcinoma organoids
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
10
The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
Fondazione Policlinico Agostino Gemelli IRCCS
Roma, Italy
RECRUITINGSuccess rate of hepatocellular carcinoma organoids integrated with host gut microbiota and peripheral blood mononuclear cells
Number of successfully created organoids from all hepatocellular carcinoma samples
Time frame: within 12 months
Analysis of hepatocellular carcinoma organoid transcriptome distribution within a reference set from The Cancer Genome Atlas
Comparison between organoids transcriptome and data from The Cancer Genome Atlas
Time frame: within 12 months
Evaluation of the concordance of somatic genetic mutations between the organoid and the original tumor
DNA organoids and original tumor sample sequencing and comparison between the somatic genetic mutations found in both models
Time frame: within 12 months
Correlation between gut microbiota community profiling and growth rate of hepatocellular carcinoma organoids
Definition of microbiota composition via DNA and RNA sequencing and correlation between specific bacteria abundance and successful organoids growth
Time frame: within 12 months
Treatment response evaluation in vitro
Evaluation of organoids' tumor cells survival after 5 days of chemotherapy treatment. Treatment will include different concentrations of sorafenib, lenvatinib, atezolizumab, bevacizumab, tremelimumab, durvalumab, regorafenib, cabozantinib. Tumor cells vitality will be assessed trough Cell TitelGlo3D Cell Viability Assay.
Time frame: Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.